In a report on the role of the SMAD4 gene as a predictive marker of therapy based on 5-FU as adjuvant therapy, Boulay et al. indicate that patients with colorectal cancer and normal SMAD4 expression gain significantly greater benefits [22]. The gene discussed is SMAD4; the disease is colorectal cancer.